血小板与淋巴细胞比值对接受免疫治疗的肺癌患者预后的预测价值：系统评价和荟萃分析。

Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.

机构信息

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

出版信息

PLoS One. 2022 May 6;17(5):e0268288. doi: 10.1371/journal.pone.0268288. eCollection 2022.

BACKGROUND

Current studies have revealed that the platelet to lymphocyte ratio (PLR) may lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a meta-analysis to explore the prognostic value of PLR in lung cancer patients receiving immunotherapy.

METHODS

We retrieved potential studies from the PubMed, Web of Science, Embase, and Scopus databases up to June 2021 and merged the hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) to evaluate the association between PLR and overall survival (OS) or progression-free survival.

RESULTS

Fourteen studies involving 1761 patients were included in our meta-analysis. The results indicated that an elevated level of pretreatment PLR was associated with poorer OS and PFS in lung cancer patients receiving immunotherapy (OS: HR = 1.88, 95% CI: 1.37-2.58; PFS: HR = HR = 1.40, 95% CI: 1.11-1.76). The association remained consistent after subgroup analysis and was robust even after sensitivity analysis.

CONCLUSIONS

PLR may be a prognostic factor of lung cancer patients receiving immunotherapy, which can lead to worse survival outcomes. However, further studies are necessary for evidence in clinical application.

背景

目前的研究表明，血小板与淋巴细胞比值（PLR）可能导致接受免疫治疗的肺癌患者预后不良。我们进行了一项荟萃分析，以探讨 PLR 对接受免疫治疗的肺癌患者的预后价值。

方法

我们从 PubMed、Web of Science、Embase 和 Scopus 数据库中检索了截至 2021 年 6 月的潜在研究，并合并了风险比（HRs）和相应的 95%置信区间（CIs），以评估 PLR 与总生存期（OS）或无进展生存期（PFS）之间的关联。

结果

我们的荟萃分析纳入了 14 项研究，共涉及 1761 例患者。结果表明，治疗前 PLR 水平升高与接受免疫治疗的肺癌患者的 OS 和 PFS 较差相关（OS：HR=1.88，95%CI：1.37-2.58；PFS：HR=1.40，95%CI：1.11-1.76）。亚组分析和敏感性分析后，该关联仍然一致，结果稳健。